GFP
EDIT icon

Gryphon Financial Partners’s Editas Medicine EDIT Stock Holding History

Gryphon Financial Partners’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-115
Closed -$4K – 351
2018
Q2 		$4K Hold
115
– – ﹤0.01% 703
2018
Q1 		$4K Buy
115
+55
+92% +$1.96K ﹤0.01% 723
2017
Q4 		$2K Buy
+60
New +$1.51K ﹤0.01% 902

Other funds holding EDIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Gryphon Financial Partners's EDIT Position: Q3 2018 in Review

Gryphon Financial Partners sold out of Editas Medicine (EDIT) in Q3 2018, closing a stake of 115 shares — an estimated $4K sold.

Gryphon Financial Partners first reported a position in EDIT in Q4 2017 and held it in 3 quarters. The position peaked at $4K in Q2 2018. 199 funds tracked by Wall St. Rank hold EDIT as of Q3 2018.

  • Gryphon Financial Partners reported no remaining Editas Medicine position as of Q3 2018 after selling out during the quarter.
  • Gryphon Financial Partners sold 115 Editas Medicine shares in Q3 2018, an estimated $4K.
  • Gryphon Financial Partners first reported a position in Editas Medicine in Q4 2017 and held it in 3 quarters.
  • Gryphon Financial Partners's Editas Medicine position peaked at $4K in Q2 2018.
  • 199 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2018.

Based on Gryphon Financial Partners's 13F filing for Q3 2018, filed 6 Nov 2018.